Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial

NCT00541554 is registered in ClinicalTrials.gov with Genovate Biotechnology Co., Ltd., as lead sponsor.

NCT NCT00541554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00541554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial
Lead sponsor
Genovate Biotechnology Co., Ltd.,
Phase
Phase 4
Overall status
Unknown status
Start date
October 31, 2007
Completion date
February 28, 2009
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia, hyperprolactinemia, weight gain